Clinical manifestations and treatment of Anderson-Fabry disease in a middle age man (RCD code: III-2B.2a)

Jurgita Plisiene, Rūta Marija Babarskienė, Dovilė Šeikytė, Eglė Ereminienė, Rokas Ereminas

Full Text:



Fabry disease is a genetic lysosomal storage disease (X-linked inheritance), also known as Anderson Fabry disease. It is a lifelong progressive disease, and it develops in patients with the lack of lysosomal enzyme alpha-galactosidase (a-Gal A) and for that reason the globotriaosylceramide(GL-3) accumulates in the endothelium of blood vessels and internal organs, then injury of various organ systems occurs, as renal insufficiency, gastrointestinal disorders, specific changes of the eye fundus, injury of the coronary arteries, hypertrophy of the left ventricle, cardiomyopathy, disorders of the nervous system, specific skin rashes (known as angioceratoma), etc. Therefore, patients with Fabry disease may occur in the practice of each speciality physician. A minor disease course, that occurs in older patients, mainly affects the cardiovascular system and may be undiagnosed. JRCD 2014; 2 (1): 15–17


Fabry disease, left ventricular hypertrophy, alpha‑galactosidase


Brady RO, Gal AE, Bradley RM et al. Enzymatic defect in Fabry’s disease: ceramidetrihexosidase deficiency. The New England Journal of Medicine 1967; 276: 1163 –1167.

Desnick RIY, Eng C. Fabry disease: alpha galactosidase A deficienca. The metabolic and molecular bases of inherited disease. 1995; 1741–2784.

Branton MH, Schiffmann R, Sabnis SG et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 2002; 81: 122.

Desnick R, Ioannou Y, Eng C. Alpha-galactosidase. A deficiency: Fabry disease. In: The Metabolic and Molecular Bases of Inherited Disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, et al. (eds.), McGraw Hill, New York 2001; 3733.

MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001; 38: 750.

Waldek S, Patel MR, Banikazemi M et al. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med. 2009; 11: 790–796.

Seydelmann N, Wanner Ch, StörkS et al. Fabry disease and the heart. Best Pract Res Clin Endocrinol Metab. 2015; 29: 195–204.

Mehta A, Beck M, Eyskens F, et al. Fabry disease: a review of current management strategies. QJM 2010; 103: 641–659.



  • There are currently no refbacks.
Journal of Rare Cardiovascular Diseases (JRCD)
John Paul II Hospital in Kraków, 80 Prądnicka Str., 31-202 Kraków, Poland
Phone: +48 (12) 614 33 99, +48 (12) 614 34 88 Fax: +48 (12) 614 34 88
Published by SoftQ sp. z o.o.
ul. Oleandry 2, 30-063 Kraków, Poland
Phone: +48 (12) 444 1650 Fax: +48 (12) 444 1659